A carregar...
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
BACKGROUND: A phase I trial was performed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics and immunogenicity of the anti-EpCAM immunotoxin (IT) MOC31PE in cancer patients. An important part of the study was to investigate whether the addition of Sandimmune (cyclosporin, CsA)...
Na minha lista:
| Publicado no: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4705890/ https://ncbi.nlm.nih.gov/pubmed/26554649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.380 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|